Moderna, Inc. (NASDAQ:MRNA) Given Consensus Recommendation of “Hold” by Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA) have earned a consensus rating of “Hold” from the twenty-three analysts that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a sell recommendation, fifteen have issued a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $53.95.

MRNA has been the topic of several recent analyst reports. UBS Group cut their target price on shares of Moderna from $78.00 to $70.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Bank of America dropped their price target on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research note on Tuesday, February 11th. Leerink Partners dropped their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research note on Thursday, January 16th. Finally, Morgan Stanley dropped their price target on Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 9th.

Moderna Stock Performance

Shares of Moderna stock opened at $24.25 on Monday. Moderna has a 52-week low of $23.15 and a 52-week high of $170.47. The stock has a market capitalization of $9.38 billion, a price-to-earnings ratio of -2.61 and a beta of 1.99. The company’s 50 day moving average price is $28.89 and its 200-day moving average price is $36.34.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm had revenue of $108.00 million for the quarter, compared to analysts’ expectations of $130.35 million. During the same quarter last year, the business earned ($3.07) earnings per share. The business’s revenue was down 35.3% on a year-over-year basis. As a group, equities research analysts forecast that Moderna will post -9.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Costello Asset Management INC purchased a new position in Moderna in the 1st quarter worth approximately $30,000. Sentry Investment Management LLC purchased a new stake in shares of Moderna during the 1st quarter worth approximately $31,000. Deseret Mutual Benefit Administrators raised its holdings in shares of Moderna by 53.3% during the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company’s stock worth $32,000 after acquiring an additional 392 shares in the last quarter. Wilmington Savings Fund Society FSB raised its holdings in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares in the last quarter. Finally, Compass Planning Associates Inc purchased a new stake in shares of Moderna during the 4th quarter worth approximately $37,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.